{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T04:25:51Z","timestamp":1766377551795,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006451","name":"Hospices Civils de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacig.2025.100450","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T18:38:43Z","timestamp":1741459123000},"page":"100450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Profiling type I and II interferon responses reveals distinct subgroups of pediatric patients with autoinflammatory disorders"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8564-9034","authenticated-orcid":false,"given":"Ana\u00efs","family":"Nombel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Perret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Trouillet-Assant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Villard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Lombard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorna","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Perrine","family":"Foray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Benezech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remi","family":"Pescarmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Khaldi-Plassart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Walzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Belot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5085-443X","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Viel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2025.100450_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jacig.2025.100450_bib2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","article-title":"Interferon-stimulated genes: what do they all do?","volume":"6","author":"Schoggins","year":"2019","journal-title":"Annu Rev Virol"},{"key":"10.1016\/j.jacig.2025.100450_bib3","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","article-title":"Interferon target-gene expression and epigenomic signatures in health and disease","volume":"20","author":"Barrat","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jacig.2025.100450_bib4","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1084\/jem.20161596","article-title":"Type I interferon\u2013mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview","volume":"213","author":"Rodero","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.jacig.2025.100450_bib5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-021-00633-9","article-title":"The type I interferonopathies: 10 years on","volume":"22","author":"Crow","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jacig.2025.100450_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jid.2021.11.031","article-title":"Type I interferons in autoimmunity","volume":"142","author":"Fernandez-Ruiz","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jacig.2025.100450_bib7","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacig.2025.100450_bib8","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/bjd.16917","article-title":"Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis","volume":"180","author":"Zhang","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jacig.2025.100450_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.20161451","article-title":"Detection of interferon alpha protein reveals differential levels and cellular sources in disease","volume":"214","author":"Rodero","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.jacig.2025.100450_bib10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.40792","article-title":"Monitoring disease activity in systemic lupus erythematosus with single-molecule array digital enzyme-linked immunosorbent assay quantification of serum interferon-\u03b1","volume":"71","author":"Mathian","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jacig.2025.100450_bib11","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1136\/annrheumdis-2019-215571","article-title":"Ultrasensitive serum interferon-\u03b1 quantification during SLE remission identifies patients at risk for relapse","volume":"78","author":"Mathian","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacig.2025.100450_bib12","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.drudis.2021.06.010","article-title":"IFN-\u03b1: a key therapeutic target for multiple autoimmune rheumatic diseases","volume":"26","author":"De Ceuninck","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jacig.2025.100450_bib13","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1002\/art.22044","article-title":"Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus","volume":"54","author":"Feng","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jacig.2025.100450_bib14","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1093\/rheumatology\/keac698","article-title":"Serum IFN\u03b12 levels are associated with disease activity and outperform IFN-I gene signature in a longitudinal childhood-onset SLE cohort","volume":"62","author":"Wahadat","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jacig.2025.100450_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"key":"10.1016\/j.jacig.2025.100450_bib16","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jacig.2025.100450_bib17","first-page":"1077","article-title":"Methods for type I interferon detection and their relevance for clinical utility and improved understanding of rheumatic diseases","volume":"37","author":"Lamot","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jacig.2025.100450_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002876","article-title":"Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider","volume":"9","author":"Burska","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jacig.2025.100450_bib19","article-title":"Development and validation of an ultrasensitive single molecule array digital enzyme-linked immunosorbent assay for human interferon-\u03b1","volume":"136","author":"Llibre","year":"2018","journal-title":"J Vis Exp"},{"key":"10.1016\/j.jacig.2025.100450_bib20","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1474-4422(13)70258-8","article-title":"Assessment of interferon-related biomarkers in Aicardi-Gouti\u00e8res syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case\u2013control study","volume":"12","author":"Rice","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacig.2025.100450_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10875-016-0359-1","article-title":"Assessment of type I interferon signaling in pediatric inflammatory disease","volume":"37","author":"Rice","year":"2017","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jacig.2025.100450_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002864","article-title":"Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider","volume":"9","author":"Rodr\u00edguez-Carrio","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jacig.2025.100450_bib23","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard-2022-223628","article-title":"2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice","volume":"82","author":"Rodr\u00edguez-Carrio","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacig.2025.100450_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003211","article-title":"Assessment of type I interferon response in routine practice in France in 2022","volume":"9","author":"Nombel","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jacig.2025.100450_bib25","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cyto.2018.10.023","article-title":"Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies","volume":"113","author":"Pescarmona","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.jacig.2025.100450_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000811","article-title":"Distinct interferon signatures stratify inflammatory and dysimmune myopathies","volume":"5","author":"Rigolet","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.jacig.2025.100450_bib27","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1002\/art.39248","article-title":"Blockade of interferon-\u03b3 normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus","volume":"67","author":"Welcher","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jacig.2025.100450_bib28","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jacig.2025.100450_bib29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/2211068215589580","article-title":"The Simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing","volume":"21","author":"Wilson","year":"2016","journal-title":"J Lab Autom"},{"key":"10.1016\/j.jacig.2025.100450_bib30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jacig.2025.100450_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12969-021-00629-8","article-title":"Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches","volume":"19","author":"Zaripova","year":"2021","journal-title":"Pediatr Rheumatol"},{"key":"10.1016\/j.jacig.2025.100450_bib32","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/annrheumdis-2021-221835","article-title":"Serum interferon-\u03b1 levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity","volume":"81","author":"Chasset","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacig.2025.100450_bib33","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3390\/biomedicines11030864","article-title":"Optimal selection of IFN-\u03b1\u2013inducible genes to determine type I interferon signature improves the diagnosis of systemic lupus erythematosus","volume":"11","author":"Demers-Mathieu","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.jacig.2025.100450_bib34","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/acr2.11618","article-title":"Type 1 interferon\u2013stimulated gene expression and disease activity in pediatric rheumatic diseases: no composite scores needed?","volume":"5","author":"Weiden","year":"2023","journal-title":"ACR Open Rheumatology"},{"key":"10.1016\/j.jacig.2025.100450_bib35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13075-015-0564-y","article-title":"Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab","volume":"17","author":"de Jong","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"10302","key":"10.1016\/j.jacig.2025.100450_bib36","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacig.2025.100450_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105532","article-title":"Contribution of the interferon score in the management of an anti-NXP2 dermatomyositis patient with calcinosis successfully treated with tofacitinib","volume":"90","author":"Robert","year":"2023","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jacig.2025.100450_bib38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/annrheumdis-2019-215918","article-title":"Type I interferon signature predicts response to JAK inhibition in haploinsufficiency of A20","volume":"79","author":"Schwartz","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacig.2025.100450_bib39","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13075-021-02451-9","article-title":"Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment","volume":"23","author":"Oliver","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jacig.2025.100450_bib40","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.1158\/0008-5472.CAN-18-2225","article-title":"An interleukin-1 signature in breast cancer treated with interleukin-1 receptor blockade: implications for treating cytokine release syndrome of checkpoint inhibitors","volume":"78","author":"Dinarello","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.jacig.2025.100450_bib41","first-page":"13","article-title":"Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-\u03b1\u2013positive breast cancer","volume":"8","author":"Casneuf","year":"2016","journal-title":"Breast Cancer (Dove Med Press)"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829325000517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829325000517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:21:14Z","timestamp":1762647674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772829325000517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2772829325000517"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2025.100450","relation":{},"ISSN":["2772-8293"],"issn-type":[{"type":"print","value":"2772-8293"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Profiling type I and II interferon responses reveals distinct subgroups of pediatric patients with autoinflammatory disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2025.100450","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100450"}}